Symbols

AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial

JAZZ

Jazz Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About JAZZ

Jazz Pharmaceuticals Public Limited Company

A company that developing drugs in the therapeutic areas of narcolepsy, oncology, pain, and psychiatry

Industry

Chemical and pharmaceutical

Established Date

Listing Date

06/01/2007

Exchange

NASDAQ Stock Exchange

Full-time Employees

2,890

Fiscal Year Ends

12-31

Website

www.jazzpharmaceuticals.com

Security Type

Common stock

Office address

Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7

Business

Develops and markets biopharmaceuticals.

Introduction

Jazz Pharmaceuticals Public Limited Company is a public limited liability company established in March 2005 under the laws of Ireland. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on the identification, development and commercialization of pharmaceutical products to meet huge medical needs. Since its establishment in 2003, it has established a commercial and development organization, and the assembled products and product candidates currently include two products on sale, as well as product candidates that are in various stages of clinical development. It currently sells two products: Xyrem (sodium oxybate), the only product approved by the U.S. Food and Drug Administration (FDA) for the treatment of cataplexy due to drowsiness and excessive daytime sleepiness; and blue-release CR (fluvoxamine maleate) for the treatment of obsessive-compulsive disorder. The Company promotes sales of these products in the United States through its experienced professional sales force of sleep specialists, neurologists, pulmonologists and psychiatrists.

Company Financials

EPS

JAZZ has released its 2026 Q2 earnings. EPS was reported at 5.71, versus the expected 6.18, missing expectations. The chart below visualizes how JAZZ has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

JAZZ has released its 2026 Q2 earnings report, with revenue of 1.21B, reflecting a YoY change of 15.55%, and net profit of 192.80M, showing a YoY change of 126.83%. The Sankey diagram below clearly presents JAZZ's revenue sources and cost distribution.